Blood Glucose in Pregnant Non-diabetic Women During Treatment With Betamethasone for Fetal Lung Maturation
Blood Glucose Levels in Pregnant Non-diabetic Women During Treatment With Betamethasone for Fetal Lung Maturation
University of Aarhus
25 participants
Nov 20, 2024
OBSERVATIONAL
Conditions
Summary
In case of threatening preterm birth, it is standard to recommend treatment with betamethasone to accelerate fetal lung maturation. In pregnant women with diabetes, treatment with betamethasone can lead to significant hyperglycemia, which may cause hypoglycemia in the neonate. Changes in blood glucose in non-diabetic women are less investigated. In this study we aim to examine changes in maternal blood glucose levels in non-diabetic women, during treatment with betamethasone, by continuous glucose monitoring. Hypotheses: Administration of betamethasone induce significant hyperglycemia in non-diabetic pregnant women during treatment.
Eligibility
Inclusion Criteria6
- Pregnant in gestational week 24+0 - 34+0 admitted with symptoms of threatened preterm birth:
- Premature contractions and shortening of the cervix, or
- Preterm premature rupture of membranes.
- Treatment with betamethasone for fetal lung maturation is planned, or started (maximum 4 hours before inclusion)
- Age over 18 years
- Read and understand Danish
Exclusion Criteria3
- Multiple pregnancy
- Diabetes
- Pre-existing maternal use of medications that affect glucose metabolism
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06794307